NOTICE:

In 2010, Optherion completed two separate business transactions, one related to its diagnostics business and one related to its therapeutics business.

With respect to its diagnostics business, in February, 2010, Optherion completed an exclusive worldwide licensing agreement with Sequenom, Inc.. Under the agreement, Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD). Please see News Room at Optherion.com for Sequenom’s press release.

With respect to its therapeutics business, also in 2010, Optherion completed a business transaction with another company. Both the company name and the transaction economics are confidential.

As a result of these two transactions, Optherion, itself, is no longer actively developing any diagnostics or therapeutics. Given this, the Optherion.com website has not been updated since year-end, 2010 albeit the nature of Optherion’s diagnostic and therapeutic endeavors are accurately represented in the website for the time period prior to the transactions.

Kindest regards,

Colin J. Foster
President & CEO
Optherion, Inc.

Mission & Values

Our Mission

Optherion’s Mission is to transform the lives of people with age-related macular degeneration (AMD) and other diseases involving the alternative complement pathway. Our aim is to change the course of disease through the parallel development of our therapeutic and diagnostic platforms.

Our therapeutics are based upon a strong underpinning of genetic and biological discoveries. They prevent vision loss in those with early stage (‘dry’) AMD and end stage renal disease in patients with dense deposit disease (DDD) or atypical hemolytic uremic syndrome (aHUS).

Our diagnostics consist of a genetic and biomarker platform that enable the detection of risk for AMD, and predict the progression of disease and treatment outcome in patients diagnosed with AMD.

Our Values

We are responsible to our patients, physicians, shareholders, employees, and communities.

Visionary Leadership
We bring foresight, ideas, and knowledge to every aspect of our business to create innovation. We lead by being transparent, open-minded, and accountable.

Integrity
We embrace the highest ethical standards, with honor and respect for our word and commitments.

Optimism and Perseverance
We pursue our mission with a sense of enthusiasm, urgency, and a ‘can-do’ spirit.

Mutual Respect and Diversity
We foster a culture of trust, cooperation, teamwork, and dependability.

Excellence
We are committed to achieving results of the highest quality.

Safety Mission

Optherion is dedicated to continuous efforts to make its operations compatible with protecting people, property, and the environment. Health, safety and environmental excellence are the responsibility of every Optherion employee.